期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

无载体放射性碘标记MIBG的制备及初步生物分布 被引量：1

Preparation and Preliminary Biodistribution of No-Carrier-Added Meta[*I]iodobenzylguanidine
下载PDF
导出
摘要 无载体放射性碘标记间碘苄胍(no-carrier-added,n.c.a.123/131I-MIBG)在肿瘤、心肌显像和神经内分泌肿瘤的治疗方面有理论上优势。首先合成了以多氟化合物为支持体的标记前体,对该前体进行了放射性碘标记、纯化和初步生物分布实验。结果显示,无载体放射性碘125I标记MIBG在正常小鼠的心、脾、肺和肾上腺中的摄取显著高于目前商用的放射性碘标记MIBG。利用该方法标记后产物不需要使用HPLC进行纯化,适用于大规模临床应用。 No-carrier-added meta-[＊I]iodobenzylguanidine（（n. c. a. ）[^123/131I]MIBG） has been considered to be promising diagnostic agents for oncology and cardiology, or as targeted radiotherapeutics for neuroendocrine tumors. The synthesis of a fluorous supported precursor for the purification without HPLC of n. c. a. [＊I]MIBG was presented and its structure was determined. The precursor was labeled with radioactive iodine and the preliminary biodistribution of n. e. a. [＊I]MIBG was studied. The uptake of n. c. a.[^125I] MIBG were significantly higher than that of c. a.[^125I]MIBG in heart, spleen, lung and adrenals. This facile preparation method of n. c. a.[＊I] MIBG would allow its wider application in clinic.
作者 樊彩云 邓新荣 刘子华 李凤林 罗志福
机构地区 中国原子能科学研究院
出处 《同位素》 CAS 2015年第3期148-154,共7页 Journal of Isotopes
关键词 间碘苄胍 无载体 多氟化合物支持体 MIBG no-carrier-added fluorous supported radioactive iodine labeling
分类号 TL923 [核科学技术—核燃料循环与材料]
  • 相关文献

参考文献22

  • 1罗全勇.MIBG及其衍生物的研究进展[J].国外医学（放射医学核医学分册）,2002,26(5):216-219. 被引量：5
  • 2Wafelman A R, Konings MCP, Hoefnagel C A, et al. Synthesis, radiolabelling, and stability of radioiodinated m-iodobenzylguanidine, a review [J]. Appl Radiat Isot, 1994, 45:997-1 007.
  • 3Vaidyanathan G and Zalutsky M. No-carrier-add-ed meta-[123 I]iodobenzylguanidine: synthesis and preliminary evaluation[J]. Nucl Med Biol, 1995, 22 : 61-64.
  • 4Samnick S, Bader J B, Mtiller M, et al. Im- proved labelling of no-carrier-added 123I-MIBG and preliminary clinical evaluation in patients with ventricular arrhythmias[J]. Nucl Med Com- mun, 1999, 20: 537-545.
  • 5Owens J, Bolster A A, Prosser J E, et al. No- carrier-added 123I-MIBG: an initial clinical study in patients with phaeochromocytoma [J]. Nucl Med Commun, 2000, 21: 437-440.
  • 6Knickmeier M, Mathejia P, Wichter T, et al. Clinical evaluation of no-carrier-added meta-[1233 I] iodobenzylguanidine for myocardial scintigraphy [J]. Eur J Nucl Med, 2000, 27: 302-307.
  • 7Knickmeier M, Schafers M and Schober O. Two years' experience using no-carrier-added meta- [123 I] iodobenzylguanidine in clinical studies[J]. EurJ Nucl Med, 2001, 28: 941.
  • 8Verberne H J, Bruin K, Habraken J B A, et al. No-carrier-added versus carrier-added 123I-me- taiodobenzylguanidine for the assessment of car- diac sympathetic nerve activity[J]. Eur J Nucl Med Mol Imaging, 2006, 33:483-490.
  • 9Barrett J A, Loyal J L, Hillier S M, et al. Com- parison of high-specific-activity ultratrace 123/131 I- MIBG and carrier added 123/131I-MIBG on effica- cy, pharmacokinetics , and tissue distribution [J]. Cancer Biother Radiopharma, 2010, 25: 299-308.
  • 10Coleman R E, Goldsmith S J, Noto R B, et al. One Year Follow-Up for the Phase I MTD Study of Ultratrace Iobenguane 1-131 in Patients with Malignant Pheochromocytoma/Paraganglioma (Pheo)[J]. Abstracts Presented at the 2nd An- nual Meeting of the North American Neuroendo- crine Tumor Society, Pancreas, 2010, 39: 272.

二级参考文献16

  • 1Vaidyanathan G, Zhao XG, Larsen RH, et al. 3-[~(211)At]-astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells [J]. Br J Cancer, 1997, 76(2): 226-233.
  • 2Cunningham SH, Maris RJ, Wheldon TE, et al. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissio [J]. Br J Cancer, 1998, 77(12): 2016-2018.
  • 3Zhuang ZP, Kung MP, Mu MU, et al. 99Tcm-labelled MIBG derivatives: Novel 99Tcm complexes as myocardial imaging agents for sympathetic neurons[J]. Bioconjugate Chem, 1999,10(2): 159-168.
  • 4Stevens MJ, Raffel DM, Allman KC, et al. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography[J]. Metabolism, 1999, 48(1): 92-101.
  • 5Merlet P, Pouillart F, Dubois-Rande JD, et al. Sympathetic nerve alterations assessed with ~(123)I-MIBG in the failing human heart[J]. J Nucl Med, 1999, 40: 224-231.
  • 6Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy [J]. J Nucl Med, 1999, 40: 917-923.
  • 7Maunoury C, Agostini D, Acar P, et al. Impairment of cardiac neuronal function in children dilated cardiomyopathy: an ~(123)I-MIBG scintigraphic Study[J]. J Ncul Med, 2000, 41:400-404.
  • 8Bengel FM, Barthel P, Matsunari I, et al. Kinetics of ~(123)I-MIBG after acute myocardial infarction and reperfusion therapy[J]. J Nucl Med, 1999, 40: 904-910.
  • 9Sakata K, Shirotani M, Yoshida H, et al. Cardiac sympathetic nervous system in early essential hypertension assessed by ~(123)I-MIBG[J]. J Nucl Med, 1999, 40:6-11.
  • 10Estorch M, Camprecios M, Flotats A, et al. Sympathetic reinnervation of cardiac allografts evaluated by ~(123)I-MIBG imaging[J]. J Nucl Med, 1999, 40:911-916.

共引文献4

同被引文献16

引证文献1

二级引证文献2

同位素
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部